AbbVie (NYSE:ABBV) Releases FY 2025 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 12.120-12.320 for the period, compared to the consensus estimate of 12.130. The company issued revenue guidance of -.

AbbVie Price Performance

NYSE ABBV traded up $12.04 during trading hours on Friday, reaching $187.69. The company’s stock had a trading volume of 4,865,886 shares, compared to its average volume of 5,849,344. AbbVie has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The company has a market capitalization of $331.68 billion, a price-to-earnings ratio of 65.04, a PEG ratio of 1.77 and a beta of 0.58. The firm’s 50-day moving average price is $176.43 and its 200-day moving average price is $184.84.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 244.01% and a net margin of 9.22%. During the same quarter in the previous year, the company posted $2.79 earnings per share. On average, equities research analysts predict that AbbVie will post 10.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research reports. Wells Fargo & Company lifted their target price on AbbVie to $195.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. BMO Capital Markets reduced their price objective on AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 12th. Sanford C. Bernstein started coverage on AbbVie in a report on Thursday, October 17th. They set a “market perform” rating and a $203.00 price objective on the stock. Bank of America reissued a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Finally, Guggenheim upped their price target on shares of AbbVie from $212.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $205.00.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.